Over the past few years, there has been a significant rise in a number of people additives towards opioid agonist drugs overdoses in the United States every day with figure stood up to 115 death toll. It has also witnessed that 21 to 29 percent of patients who are prescribed opioids for chronic pain misuse them, with 8 to 12 percent developing an opioid use disorder. The major companies are organized awareness programs in Asia-Pacific and Middle East region to prescribe painkillers to help patients overcome opiophobia. The opioids drugs is a type of narcotic pain medication that applicable for treatment of severe pain. It is used as an anesthesia, cough suppressant, diarrhea suppressant and to reduce surgical pain. As the numbers of critically ill patients are increasing, demand for orthopedic diseases is also on the rise, leading to a growing demand for opioids drugs.
- Upsurging Geriatric Population leading to Increased Prevalence of Cancer, Postsurgical Pain, Lower Back Pain, and Many Others
- Increasing Surgical Procedures and Technological Advancements
- Increasing Use of Methadone, Buprenorphine, and Extended-Release Naltrexone
- Growing Adoption of Opioids Drugs in Surgical Treatments and Pain Management
- Stringent Government Regulations on Manufacturing Opioids Agonist Drugs
- Continues Products Development and R&D has Introduced Number of Cheaper Substitutes
Rising Demands of Opioids Drugs in Cough Suppressant and Diarrhea Suppressant. and Growing Palliative Care Facilities Boost the Opioids Drugs Market
Players Covered in the Study are:
Purdue Pharma L.P (United States), Allergan PLC (Ireland), Sanofi S.A (France), Pfizer, Inc. (United States), Janssen Pharmaceuticals, Inc. (Belgium), Endo Pharmaceuticals, Inc (United States), Actavis Plc (United States), Egalet Corporation (United States), Sun Pharmaceuticals (India), Boehringer Ingelheim GmbH (Germany). and Titan Pharmaceuticals, Inc. (TTNP) (United States)
The Global Opioids Agonist Drugs market is gaining huge competition due to involvement of European and United States companies that constantly invest in research & development to meet market expectation with new innovation.
In April 2019, U.S. Food and Drug Administration launched a public education campaign which is beneficial in providing safe removal of unused opioid pain medicines from homes. It also introduced a “Remove and Risk” Campaign that telecast in television, radio and print public announcements that can be used by different organizations, individuals and healthcare providers.
List of players that can be included in the study on immediate basis are Mallinckrodt Pharmaceuticals (United Kingdom) and Allergan, Plc (Ireland).